At the recent Life Science Summit held at Hogan Lovells’ Tokyo office on October 4, 2023, the panel discussion focused on significant challenges linked with the APAC life science industry, particularly relevant to General Counsels of Japanese enterprises. The special team of panelists consisted of Dr. Frederick Chen, the APAC lead for Hogan Lovells’ life science and healthcare division, and partners from the firm’s global offices – Melissa Bianchi (Washington DC), Penny Powell (London), Karen Taylor (Northern Virginia), and Hein van den Bos (Amsterdam).
The panelists’ discussion spanned a wide range of matters including the impact of drug pricing (drug price listing) and reimbursement payments on product commercialization, supply chain planning, preparation for going public, significant regulatory changes in the US and EU, cross-border issues in licensing transactions, as well as the latest trends pertaining to artificial intelligence (AI) and digital health.
Given the rapidly evolving nature of the life science industry within the APAC region and the increasing regulatory challenges it faces, it is critical for enterprises to be armed with insights and perspectives shared by such experienced legal professionals. This enables them to not only anticipate potential legal pitfalls but also to strategize their growth plans efficiently.
To learn more about the comprehensive discussion at the Summit and dive deeper into these topics, please refer to the full article here.